Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
VBIV Stock Summary
In the News

VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Misses Revenue Estimates
VBI Vaccines, Inc. (VBIV) came out with a quarterly loss of $2.43 per share versus the Zacks Consensus Estimate of a loss of $2.27. This compares to loss of $2.40 per share a year ago.

VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans
VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.

VBI Vaccines to focus on hep B treatments, conduct 1-for-30 reverse stock split
VBI Vaccines Inc. VBIV, -0.96% said Tuesday it is planning to focus its efforts on hepatitis B, as part of a reorganization that will see it cut operating costs and headcount by 30% to 35% and conduct a reverse stock split. Cambridge, Mass.

VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Misses Revenue Estimates
VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -14.29% and 85.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

VBI Vaccine (VBIV) Inks Deal With Agenus for Brain Cancer Study
VBI Vaccines (VBIV) enters into a partnership with Agenus to conduct a study evaluating the former's VBI-1901 in combination with the latter's balstilimab for primary glioblastoma.

VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook
VBI Vaccines has not been immune to sell-off with their share price shrinking by roughly 75% over the past year despite the company making significant headway both clinically and commercially. VBIV is still in my Compounding Healthcare "Bio Boom" speculative portfolio. The company's efforts in 2022 have fortified that position.

VBI Vaccines (VBIV) Stock: Why It Fell 10.72% After Hours
The stock price of VBI Vaccines (VBIV) fell by 10.72% after hours in the most recent trading session. This is why.

Why Ocugen, Sorrento Therapeutics, and VBI Vaccines Are on the Move Today
Healthcare has become a bona fide stock picker's market this year.

3 Biotech Penny Stocks That Climbed in After-Hours Trading
Check these three biotech penny stocks out for your watchlist right now The post 3 Biotech Penny Stocks That Climbed in After-Hours Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis
VBI Vaccines recently reported updated data from their VBI-1901 candidate in recurrent Glioblastoma. The company publicized the median overall survival and 18-month overall survival data are outperforming historical controls. VBI-1901 is showing its ability to have an impact on the tumor response and clinical outcomes. One patient who is still on protocol has been progression-free for over two years.
VBIV Financial details
VBIV Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.05 | 0.56 | 0.15 | 0.07 | 0 | |
Net income per share | -0.98 | -15.1 | -6.11 | -7.85 | -0.55 | |
Operating cash flow per share | -0.69 | -12.23 | -6.47 | -4.7 | -0.29 | |
Free cash flow per share | -0.78 | -13.16 | -6.6 | -4.93 | -0.3 | |
Cash per share | 0.9 | 11.1 | 16.37 | 14.32 | 0.24 | |
Book value per share | 1.49 | 22.17 | 23.6 | 16.93 | 0.25 | |
Tangible book value per share | 0.48 | 6.35 | 14.75 | 9.36 | 0.01 | |
Share holders equity per share | 1.49 | 22.17 | 23.6 | 16.93 | 0.25 | |
Interest debt per share | 0.26 | 4.49 | 2.83 | 4.3 | 0.22 | |
Market cap | 3.15B | 164.84M | 600.24M | 596.58M | 3.03B | |
Enterprise value | 3.11B | 135.47M | 507.36M | 506.68M | 3.02B | |
P/E ratio | -49.11 | -2.74 | -13.49 | -8.94 | -21.5 | |
Price to sales ratio | 939.22 | 74.22 | 565.73 | 945.45 | 2.8K | |
POCF ratio | -69.2 | -3.38 | -12.76 | -14.95 | -41.12 | |
PFCF ratio | -61.16 | -3.15 | -12.49 | -14.24 | -38.83 | |
P/B Ratio | 32.11 | 1.87 | 3.5 | 4.15 | 47.23 | |
PTB ratio | 32.11 | 1.87 | 3.5 | 4.15 | 47.23 | |
EV to sales | 925.74 | 60.99 | 478.19 | 802.98 | 2.79K | |
Enterprise value over EBITDA | -52.42 | -2.94 | -11.63 | -7.45 | -36.91 | |
EV to operating cash flow | -68.21 | -2.78 | -10.78 | -12.7 | -40.98 | |
EV to free cash flow | -60.28 | -2.59 | -10.56 | -12.09 | -38.7 | |
Earnings yield | -0.02 | -0.36 | -0.07 | -0.11 | -0.05 | |
Free cash flow yield | -0.02 | -0.32 | -0.08 | -0.07 | -0.03 | |
Debt to equity | 0.4 | 0.38 | 0.22 | 0.46 | 1.42 | |
Debt to assets | 0.29 | 0.28 | 0.18 | 0.32 | 0.59 | |
Net debt to EBITDA | 0.76 | 0.64 | 2.13 | 1.32 | 0.13 | |
Current ratio | 2.64 | 1.58 | 7.61 | 4 | 2.1 | |
Interest coverage | -18.56 | -23.86 | -16.11 | -14.38 | -20.42 | |
Income quality | 0.72 | 0.89 | 1.02 | 0.57 | 0.65 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 6.2 | 6.34 | 19.46 | 60.75 | 51.87 | |
Research and developement to revenue | 11.47 | 11.86 | 14 | 31 | 14.33 | |
Intangibles to total assets | 0.48 | 0.52 | 0.31 | 0.31 | 0.39 | |
Capex to operating cash flow | 0.13 | 0.08 | 0.02 | 0.05 | 0.06 | |
Capex to revenue | -1.79 | -1.65 | -0.94 | -3.16 | -4.01 | |
Capex to depreciation | -11.06 | -3.05 | -0.61 | -1.09 | -2.11 | |
Stock based compensation to revenue | 0.99 | 1.77 | 4.98 | 15.26 | 8.96 | |
Graham number | 5.73 | 86.78 | 56.98 | 54.7 | 1.75 | |
ROIC | -4.68 | -1.76 | -2.33 | 1.74 | -6.04 | |
Return on tangible assets | -0.9 | -1.01 | -0.31 | -0.46 | -1.49 | |
Graham Net | 0.31 | 2.75 | 11.35 | 6.66 | -0.1 | |
Working capital | 38.35M | 17.21M | 114.69M | 97.7M | 40.75M | |
Tangible asset value | 31.62M | 25.29M | 107.29M | 79.53M | 3.69M | |
Net current asset value | 22.26M | 13.02M | 94.37M | 63.89M | -13.23M | |
Invested capital | 0.14 | 0.18 | 0.1 | 0.22 | 0.81 | |
Average receivables | 99.5K | 128.5K | 139K | 42.5K | 51K | |
Average payables | 3.93M | 3.59M | 2.43M | 4.01M | 8.63M | |
Average inventory | 849.5K | 993K | 1.61M | 2.36M | 4.59M | |
Days sales outstanding | 6.09 | 33.03 | 26.49 | 4.63 | 31.71 | |
Days payables outstanding | 490.15 | 52.04 | 148.66 | 145.05 | 419.93 | |
Days of inventory on hand | 73.74 | 49.64 | 85.68 | 87.3 | 213.61 | |
Receivables turnover | 59.91 | 11.05 | 13.78 | 78.88 | 11.51 | |
Payables turnover | 0.74 | 7.01 | 2.46 | 2.52 | 0.87 | |
Inventory turnover | 4.95 | 7.35 | 4.26 | 4.18 | 1.71 | |
ROE | -0.65 | -0.68 | -0.26 | -0.46 | -2.2 | |
Capex per share | -0.09 | -0.92 | -0.14 | -0.23 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.01 | 0.04 | 0.04 | 0 | 0.06 | |
Net income per share | -2.98 | -7.85 | -3.26 | -0.08 | -4.34 | |
Operating cash flow per share | -2.31 | -2.03 | -2.01 | -0.07 | -2.51 | |
Free cash flow per share | -2.37 | -2.15 | -2.16 | -0.08 | -2.58 | |
Cash per share | 11.77 | 9.57 | 9.71 | 0.24 | 4.69 | |
Book value per share | 15.05 | 12.26 | 9.74 | 0.25 | 5.22 | |
Tangible book value per share | 7.44 | 4.87 | 2.79 | 0.01 | -1.81 | |
Share holders equity per share | 15.05 | 12.26 | 9.74 | 0.25 | 5.22 | |
Interest debt per share | 4 | 4 | 6.18 | 0.21 | 6.3 | |
Market cap | 428.71M | 208.8M | 182.28M | 3.03B | 78.33M | |
Enterprise value | 360.76M | 159.73M | 150.63M | 3.02B | 90.31M | |
P/E ratio | -4.18 | -0.77 | -1.62 | -38.58 | -0.52 | |
Price to sales ratio | 3.4K | 603.47 | 575.01 | 10.34K | 161.51 | |
POCF ratio | -21.52 | -11.97 | -10.55 | -159.1 | -3.62 | |
PFCF ratio | -20.97 | -11.27 | -9.81 | -147.83 | -3.53 | |
P/B Ratio | 3.31 | 1.98 | 2.17 | 47.23 | 1.74 | |
PTB ratio | 3.31 | 1.98 | 2.17 | 47.23 | 1.74 | |
EV to sales | 2.86K | 461.64 | 475.18 | 10.31K | 186.2 | |
Enterprise value over EBITDA | -23.47 | -7.2 | -7.33 | -148.95 | -4.88 | |
EV to operating cash flow | -18.11 | -9.15 | -8.72 | -158.55 | -4.17 | |
EV to free cash flow | -17.65 | -8.62 | -8.11 | -147.32 | -4.07 | |
Earnings yield | -0.06 | -0.32 | -0.15 | -0.01 | -0.48 | |
Free cash flow yield | -0.05 | -0.09 | -0.1 | -0.01 | -0.28 | |
Debt to equity | 0.5 | 0.63 | 1.05 | 1.42 | 1.85 | |
Debt to assets | 0.33 | 0.39 | 0.51 | 0.59 | 0.65 | |
Net debt to EBITDA | 4.42 | 2.21 | 1.54 | 0.51 | -0.65 | |
Current ratio | 3.31 | 2.29 | 2.77 | 2.1 | 1.75 | |
Interest coverage | -15.65 | -21.21 | -16.95 | -11.57 | -10.1 | |
Income quality | 0.94 | 0.38 | 0.69 | 0.9 | 0.78 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 86.75 | 43.6 | 44.86 | 54.22 | 0 | |
Research and developement to revenue | 18.75 | 16.31 | 15.72 | 8.59 | 6.5 | |
Intangibles to total assets | 0.34 | 0.37 | 0.35 | 0.39 | 0.47 | |
Capex to operating cash flow | 0.03 | 0.06 | 0.08 | 0.08 | 0.02 | |
Capex to revenue | -4.09 | -3.11 | -4.1 | -4.96 | -1.1 | |
Capex to depreciation | -1.09 | -1.99 | -2.47 | -2.79 | -1.05 | |
Stock based compensation to revenue | 19.86 | 7.1 | 7.61 | 7.94 | 4.15 | |
Graham number | 31.76 | 46.54 | 26.73 | 0.65 | 22.59 | |
ROIC | 1.53 | -19.74 | 3.55 | -1.18 | -0.7 | |
Return on tangible assets | -0.2 | -0.62 | -0.25 | -0.21 | -0.55 | |
Graham Net | 4.77 | 2.29 | 0.01 | -0.08 | -4.47 | |
Working capital | 78.36M | 52.22M | 61.54M | 40.75M | 22.26M | |
Tangible asset value | 64.04M | 41.94M | 23.99M | 3.69M | -15.61M | |
Net current asset value | 47.91M | 26.15M | 8.02M | -13.23M | -31.6M | |
Invested capital | 0.26 | 0.32 | 0.62 | 0.81 | 1.16 | |
Average receivables | 2.16M | 2.66M | 2.47M | 3.3M | 2.81M | |
Average payables | 4.1M | 4.77M | 8.64M | 12.32M | 11.41M | |
Average inventory | 3.32M | 4.05M | 4.92M | 6.2M | 6.68M | |
Days sales outstanding | 2.05K | 636.76 | 704.67 | 1.27K | 275.38 | |
Days payables outstanding | 128.33 | 200.45 | 392.94 | 350.83 | 248.76 | |
Days of inventory on hand | 132.58 | 144.53 | 195.22 | 178.46 | 171.15 | |
Receivables turnover | 0.04 | 0.14 | 0.13 | 0.07 | 0.33 | |
Payables turnover | 0.7 | 0.45 | 0.23 | 0.26 | 0.36 | |
Inventory turnover | 0.68 | 0.62 | 0.46 | 0.5 | 0.53 | |
ROE | -0.2 | -0.64 | -0.33 | -0.31 | -0.83 | |
Capex per share | -0.06 | -0.13 | -0.15 | -0.01 | -0.06 |
VBIV Frequently Asked Questions
What is VBI Vaccines Inc. stock symbol ?
VBI Vaccines Inc. is a US stock , located in Cambridge of Ma and trading under the symbol VBIV
What is VBI Vaccines Inc. stock quote today ?
VBI Vaccines Inc. stock price is $2.75 today.
Is VBI Vaccines Inc. stock public?
Yes, VBI Vaccines Inc. is a publicly traded company.